Loading...
Market
What will be the outcome of Asceneuron's Phase 2 clinical trials for ASN51 by the end of 2025?
2
Resolution / Starting Odds
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Asceneuron's official press releases, clinical trial registries, and scientific publications
Story
Asceneuron Raises $100M in Series C for Alzheimer's Drug Development
Jul 16, 2024, 08:01 AM
Swiss biotech company Asceneuron announced it has raised $100 million in an oversubscribed Series C financing round. The funding, led by Novo Holdings, will be used to advance the clinical development of its Alzheimer's disease drug, targeting Tau protein aggregation. Investors include EQT Life Sciences, SofinnovaVC, and other notable backers. The raised capital will support the progression of Asceneuron's lead asset, ASN51, into Phase 2 clinical trials. The drug is being developed as an oral therapy. Professor Scheltens has joined the board to further bolster the company's expertise.
View original story
Similar markets
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%